Trials / Active Not Recruiting
Active Not RecruitingNCT04901195
A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 658 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimekizumab | Subjects will receive bimekizumab at pre-specified time-points. |
Timeline
- Start date
- 2021-05-27
- Primary completion
- 2026-07-28
- Completion
- 2026-07-28
- First posted
- 2021-05-25
- Last updated
- 2026-03-27
Locations
145 sites across 19 countries: United States, Australia, Belgium, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Netherlands, Poland, Spain, Switzerland, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04901195. Inclusion in this directory is not an endorsement.